Insider Selling: Cardlytics, Inc. (NASDAQ:CDLX) CFO Sells $32,494.18 in Stock

Cardlytics, Inc. (NASDAQ:CDLX) CFO Alexis Desieno sold 8,854 shares of Cardlytics stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $3.67, for a total value of $32,494.18. Following the completion of the sale, the chief financial officer now owns 121,976 shares of the company’s stock, valued at approximately $447,651.92. The trade was a 6.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Alexis Desieno also recently made the following trade(s):

• On Friday, November 15th, Alexis Desieno sold 25,118 shares of Cardlytics stock. The shares were sold at an average price of $3.43, for a total transaction of $86,154.74.

Cardlytics Trading Down 2.6 %

Shares of NASDAQ CDLX opened at $3.35 on Thursday. Cardlytics, Inc. has a twelve month low of $2.89 and a twelve month high of $20.52. The stock has a market cap of $170.25 million, a price-to-earnings ratio of -0.55 and a beta of 1.53. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40. The company’s fifty day moving average is $3.89 and its 200-day moving average is $4.77.

Cardlytics (NASDAQ:CDLX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The firm had revenue of $67.06 million for the quarter, compared to analyst estimates of $57.77 million. During the same period in the previous year, the company posted ($0.26) earnings per share. The company’s revenue for the quarter was down 15.1% on a year-over-year basis. Equities research analysts predict that Cardlytics, Inc. will post -1.52 EPS for the current year.

Hedge Funds Weigh In On Cardlytics

Several institutional investors and hedge funds have recently modified their holdings of CDLX. Geode Capital Management LLC lifted its stake in Cardlytics by 7.5% in the third quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock valued at $3,371,000 after buying an additional 73,484 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Cardlytics by 6.8% during the second quarter. Marshall Wace LLP now owns 814,281 shares of the company’s stock worth $6,685,000 after acquiring an additional 52,081 shares during the period. RBF Capital LLC lifted its position in Cardlytics by 311.9% in the 3rd quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after acquiring an additional 369,620 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Cardlytics by 3.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,343 shares of the company’s stock worth $1,249,000 after purchasing an additional 11,388 shares during the period. Finally, GSA Capital Partners LLP increased its holdings in Cardlytics by 1,273.2% during the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock worth $1,223,000 after purchasing an additional 354,474 shares in the last quarter. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a report on Thursday, November 7th. Craig Hallum raised Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Finally, Evercore ISI began coverage on Cardlytics in a research note on Friday, October 11th. They set an “in-line” rating and a $4.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Cardlytics currently has a consensus rating of “Hold” and a consensus price target of $6.92.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.